▲ +79.16% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Progenity in the last 3 months. The average price target is $9.80, with a high forecast of $12.00 and a low forecast of $5.00. The average price target represents a 79.16% upside from the last price of $5.47.
The current consensus among 5 contributing investment analysts is to buy stock in Progenity.
Progenity, Inc., a biotechnology company, provides complex molecular and specialized testing services to physicians, clinicians, and their patients in the United States. It offers testing services for common hereditary disorders, cystic fibrosis, spinal muscular atrophy, fragile X syndrome, and Jewish genetic diseases; pan-ethnic carrier screening services; non-invasive prenatal, miscarriage, and pharmacogenetic testing services; and ovarian assessment reports for women. The company also provides pediatric testing services. Progenity, Inc. was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November, 2013. The company was incorporated in 2012 and is based in San Diego, California with a laboratory in Ann Arbor, Michigan. It has a bill payment location in Detroit, Michigan.